688566.SHG Jiangsu Jibeier Pharmaceutical Co Ltd
- Market cap
- CNY 5.37B
- P/E
- 22.3x
- P/B
- 2.04x
- ROE
- 7.9%
- Dividend yield
- 1.93%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688566.SHG undervalued?
Graham number688566.SHG trades 42.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jiangsu Jibeier Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Jiangsu Jibeier Pharmaceutical Co Ltd yet.
Jiangsu Jibeier Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jiangsu Jibeier Pharmaceutical Co Ltd
Jiangsu Jibeier Pharmaceutical Co., Ltd., a pharmaceutical company, engages in the drug research and development and production in China. The company's products cover multiple therapeutic areas such as increasing white blood cells, fighting hypertension, enhancing immunity, treating joint diseases, fighting eye infections, treating bronchitis, protecting liver function, etc. It is also developing drugs for the treatment of depression, tumors, stomach and gastric diseases, an…
Full company profileJiangsu Jibeier Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Jiangsu Jibeier Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 444M | 452M | 485M | 543M | 566M | 510M | 655M | 861M | 897M | 965M | 979M |
| Gross Profit | 376M | 385M | 421M | 479M | 502M | 448M | 579M | 764M | 801M | 965M | 882M |
| Operating Income | 82.5M | 93.0M | 114M | 130M | 151M | 134M | 176M | 249M | 255M | 253M | 231M |
| EBITDA | 104M | 105M | 126M | 143M | 162M | 146M | 188M | 259M | 264M | 309M | 229M |
| Net Income | 76.9M | 77.5M | 96.6M | 113M | 130M | 115M | 155M | 219M | 219M | 259M | 198M |
| EPS | 0.55 | 0.55 | 0.69 | 0.81 | 0.77 | 0.61 | 0.83 | 1.17 | 1.13 | 1.30 | 0.99 |
| Balance Sheet | |||||||||||
| Total Assets | 482M | 528M | 478M | 596M | 1.75B | 1.82B | 1.96B | 2.21B | 2.53B | 2.72B | 2.78B |
| Total Liabilities | 119M | 86.9M | 120M | 125M | 171M | 210M | 270M | 299M | 274M | 267M | 250M |
| Shareholders' Equity | 357M | 434M | 351M | 464M | 1.57B | 1.60B | 1.69B | 1.90B | 2.25B | 2.43B | 2.52B |
| Cash & Short-term Investments | 133M | 201M | 125M | 193M | 1.29B | 1.23B | 994M | 730M | 903M | 781M | 602M |
| Total Debt | 19.0M | - | - | - | - | - | - | 9.91M | 20.8M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 39.3M | 112M | 98.0M | 115M | 117M | 151M | 151M | 160M | 215M | 248M | - |
| Capital Expenditure | 46.7M | 18.8M | 8.19M | 30.2M | 23.7M | 83.8M | 293M | 357M | 175M | 115M | 83.4M |
| Free Cash Flow | -7.40M | 92.9M | 89.8M | 85.2M | 93.7M | 66.8M | -142M | -198M | 40.8M | 134M | 183M |
| Ratios | |||||||||||
| ROE | 21.6% | 17.9% | 27.5% | 24.3% | 8.3% | 7.2% | 9.2% | 11.5% | 9.8% | 10.6% | 7.9% |
| ROA | 16.0% | 14.7% | 20.2% | 19.0% | 7.4% | 6.3% | 7.9% | 9.9% | 8.7% | 9.5% | 7.1% |
| Net Profit Margin | 17.3% | 17.1% | 19.9% | 20.8% | 22.9% | 22.5% | 23.6% | 25.4% | 24.5% | 26.8% | 20.3% |
| Debt to Equity | 0.05x | - | - | - | - | - | - | 0.01x | 0.01x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Jiangsu Jibeier Pharmaceutical Co Ltd dividends
- Dividend yield
- 1.93%
- Forward dividend
- 0.52 CNY
- Payout ratio
- 40.1%
- Ex-dividend date
- Oct 15, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 104M | 0.52 | 40.1% |
| 2024 | CNY 103M | 0.53 | 46.9% |
| 2023 | CNY 44.9M | 0.24 | 20.5% |
| 2022 | CNY 89.7M | 0.48 | 58.0% |
| 2021 | CNY 89.7M | 0.48 | 78.1% |
| 2020 | CNY 44.9M | 0.27 | 34.6% |
| 2019 | CNY 10.9M | 0.08 | 9.6% |
| 2018 | CNY 169M | 1.21 | 175.1% |
| 2017 | CNY 5.02M | 0.04 | 6.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Jiangsu Jibeier Pharmaceutical Co Ltd
- Insiders 70.35%
- Institutions 3.10%
- Public & others 26.55%
- Shares outstanding 201M
- Free float 63.0M
Jiangsu Jibeier Pharmaceutical Co Ltd company profile
- Company name
- Jiangsu Jibeier Pharmaceutical Co Ltd
- Ticker
- 688566.SHG
- ISIN
- CNE100004041
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,354
- Fiscal year end
- December
- Address
- Zhenjiang High-tech Industrial Development Park, Zhenjiang, China
- Phone
- 86 51 1888 98101
- Website
- jbepharm.com
About Jiangsu Jibeier Pharmaceutical Co Ltd
Jiangsu Jibeier Pharmaceutical Co., Ltd., a pharmaceutical company, engages in the drug research and development and production in China. The company's products cover multiple therapeutic areas such as increasing white blood cells, fighting hypertension, enhancing immunity, treating joint diseases, fighting eye infections, treating bronchitis, protecting liver function, etc. It is also developing drugs for the treatment of depression, tumors, stomach and gastric diseases, and other diseases. In addition, the company offers its products in tablets, capsules, and eye drops forms. Jiangsu Jibeier Pharmaceutical Co., Ltd. was founded in 2001 and is based in Zhenjiang, China.
Jiangsu Jibeier Pharmaceutical Co Ltd management
10- Mr. Zhongyi GengGM & Chairman of the Board · born 1963
- Mr. Xinjun YuVice Chairman of the Board & Deputy GM · born 1961
- Mr. Suofu ZhaoFinancial Director · born 1967
- Mr. Haidao LiExecutive Vice President of the Research Institute · born 1983
- Mr. Jianzhong ZhaiBoard Secretary · born 1972
- Mr. Xufeng QinDeputy Director of the Formulation Laboratory · born 1974
- Mr. Zhaoguang LiDirector of the Synthesis Office of the Research Institute · born 1981
- Ms. Ying WuDeputy General Manager · born 1952
- Mr. Xiugen WuResearch Institute Director · born 1965
- Zhi Lei ZhuAccounting Supervisor